Rapid diagnostic tests based on paper microfluidics

Paperdrop Diagnostics S.L. develops rapid diagnostic tests based on paper microfluidics, dealing with non-covered medical needs and emerging health problems, with special interest in critical and prevalent diseases. Our technology is based on lateral flow immunoassays, similar to pregnancy tests, which are being optimized to act as a clinical decision tool. A single drop of patient’s fluid (e.g. blood) is required to carry out the test using a paper sensor. It is a low-cost and easy-to-use tool that presents improved sensitivity and specificity than current lab tests.

Meet our team

Equipment-free

No need of any equipment, just a device as simple as a pregnancy test and one drop of sample.

Ultrasensitivity

Molecular and genetic biomarkers along with new signal detection and visualization strategies.

Low cost

Paper has unlimited capacities, is easy to be manufactured and is totally reciclable.

Fast & Easy

Just one drop on the paper, wait about 5 minutes and that’s it: the diagnostic is done.

Our process

PHASE I

Biomarker selection

The clinically promising biomarkers are deployed to obtain the most effective and affordable solution for practitioners and patients on paper-based tests.

Bioreceptor implementation

The most sensitive receptors for target biomarkers are identified, adapted and implemented through cutting-edge nanotechnology.

Signal enhancing

Ultrasensitivity is achieved through new signaling strategies and with the use of nanoparticles, nanomaterials and fitted chemistry.

Try on samples

The paper-based diagnostic test is implemented using synthetic samples optimizing the analytical performance and then consolidated on real samples.

Minimum Viable Product

Phase I concludes with the obtention of the totally functional demonstrator, the MVP, as a pre-commercial product with all the diagnostic test capabilities.

PHASE II

Validation

Evaluation and optimization of the MVP in real clinical samples in a controlled study in comparison with the current gold standard diagnostic technology.

Industrial design

Definition and optimization of the final features of the commercial product to facilitate the manufacturing, storage and usability of the diagnostic test.

Clinical assay

A clinical trial and usability test are performed in a controlled clinical setting in order to validate the efficacy, accuracy and reproducibility of the test.

Certification

The proper certifications for manufacturing, commercial distribution and the use for diagnosis are obtained for the target markets.

Regulatory agency approval

Approval application through the clinical evidence of usability and the conformity with its applicable requirements of safety and performance.

FLAGSHIP PRODUCT

Resistgene TM

Antimicrobial Resistance (AMR) is a growing threat to public health as bacteria and fungi become resistant to drugs. Without action, deaths could reach 10M annually by 2050. Urgent, affordable monitoring tools are crucial, and the EU’s One Health Action Plan seeks to combat AMR through enhanced surveillance, responsible antibiotic use, and research into new treatments.

In this context, PaperdropDx has developed ResistgeneTM a revolutionary assay that offers a near-patient testing solution for detecting multiple AMR genes focusing on carbapenemases, a critical resistance mechanism.